SCHEMBL1187348

SCHEMBL1187348

O=C(O)CC1CCC(OC(=O)N2CCc3cc(NC(=O)Nc4cccnc4)ccc3C2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 3/20 0.48
CYP1A2 P05177 2/20 0.48
PKM P14618 2/20 0.48
TP53 P04637 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
TSHR P16473 1/20 0.48
NFKB1 P19838 1/20 0.48
THPO P40225 1/20 0.48
HIF1A Q16665 1/20 0.48
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
NAMPT P43490 5/20 0.41
DGAT1 O75907 1/20 0.41
SYK P43405 1/20 0.40
EPHX2 P34913 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1187351 1.00 NPC1 (0.48) NPC1RAB9ACYP1A2PKMTP53
SCHEMBL1188003 0.92 NPC1 (0.49) NPC1RAB9ACYP1A2PKMTP53
SCHEMBL1188004 0.92 NPC1 (0.49) NPC1RAB9ACYP1A2PKMTP53
SCHEMBL1188339 0.90 DGAT1 (0.50) NPC1RAB9ATP53SMN1; SMN2NAMPT
SCHEMBL1188342 0.90 DGAT1 (0.50) NPC1RAB9ATP53SMN1; SMN2NAMPT
SCHEMBL1189686 0.90 NAMPT (0.42) PKMNAMPTDGAT1SYKROCK2
SCHEMBL1189690 0.90 NAMPT (0.42) PKMNAMPTDGAT1SYKROCK2
SCHEMBL1187921 0.89 KDM4E (0.41) NPC1RAB9ASMN1; SMN2NAMPTSYK
SCHEMBL1187924 0.89 KDM4E (0.41) NPC1RAB9ASMN1; SMN2NAMPTSYK
SCHEMBL1187908 0.88 SYK (0.40) NPC1RAB9ANAMPTDGAT1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735425-B2 Tetrahydroisoquinoline derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 US disclosed
EP-2256105-B1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-12-04 EP disclosed
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-10 US disclosed
EP-2256105-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DGAT1, DGAT2, DLAT NPC1 269/4885RAB9A 1878/4885CYP1A2 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.